Abstract

Provided herein are compositions and methods for increasing an immune response in a subject, immunizing a subject and/or treating a disease in a subject that relate to keratinocytes. It is a surprising finding of the present invention that modulation of an XBP1 pathway creates a keratinocyte that is itself an immune modulator, or adjuvant. In some embodiments, the concentration of antigen is increased in the vicinity of the keratinocyte, further increasing the immune response by effector cells within that vicinity.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/12 - Viral antigens
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

A fiber optic based sensing system and method includes a. functionalized optical fiber based sensor including an engineered sensing layer, a light source structured to generate light and couple the light into an input of the functionalized optical fiber based sensor, and an interrogator including a photodetector coupled to the functionalized optical fiber based sensor to receive transmitted or reflected tight, a transimpedance amplifier (TIA) circuit coupled to an output of the photodetector, a controller coupled to an output of the TIA circuit, and a transmitter (e.g., a wired or wireless transmitter) coupled to the controller.

IPC Classes  ?

• G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
• H03F 3/08 - Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements with semiconductor devices only controlled by light
• H04B 10/67 - Optical arrangements in the receiver

Abstract

Neuroblastoma (NB) remains a leading cause of childhood cancer morbidity and mortality. Heritable activating mutations are present in the anaplastic lymphoma kinase (ALK) oncogene and these same mutations are frequently somatically acquired during high-risk NB tumorigenesis. ALK has been established as a tractable molecular target in NB and provides the rationale for the clinical development of ALK inhibition therapy. Anti-ALK antibodies and antigen binding fragments thereof are provided along with methods of use thereof.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/52 - Hydrogels or hydrocolloids
• C07K 14/745 - Blood coagulation or fibrinolysis factors
• C07K 14/75 - Fibrinogen

Abstract

The invention relates to dental bone grafting devices and magnesium meshes having features that are designed to corrode and/or absorb progressively, e.g., in stages, in order to improve dental bone regeneration, as well as methods for preparing the meshes. The meshes include a framework, and a geometric design is formed within the framework that includes design features. The geometric design and design features are selected and manipulated to provide the progressive corrosion and/or absorption profile of the mesh.

IPC Classes  ?

• A61C 8/02 - Means for transfixation of natural teeth
• A61L 27/04 - Metals or alloys
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The invention relates to biodegradable iron alloy-containing compositions for use in preparing medical devices. In addition, biodegradable crystalline and amorphous compositions of the invention exhibit properties that make them suitable for use as medical devices for implantation into a body of a patient. The compositions include elemental iron, and one or more elements selected from manganese, magnesium, zirconium, zinc and calcium. The compositions can be prepared using a high energy milling technique. The resulting compositions and the devices formed therefrom are useful in various surgical procedures, such as but not limited to orthopedic, craniofacial, tracheal, and cardiovascular.

IPC Classes  ?

• A61L 31/02 - Inorganic materials
• A61L 31/14 - Materials characterised by their function or physical properties
• C22C 33/10 - Making cast-iron alloys including procedures for adding magnesium
• C22C 38/00 - Ferrous alloys, e.g. steel alloys
• C22C 38/04 - Ferrous alloys, e.g. steel alloys containing manganese
• C22C 38/14 - Ferrous alloys, e.g. steel alloys containing titanium or zirconium
• C22C 45/02 - Amorphous alloys with iron as the major constituent

Abstract

Methods are disclosed for generating a target mean arterial pressure (MAP) for a patient during a surgery. In some implementations, the disclosed methods include calculating the target MAP based on the age, biological sex, emergent surgery status, and American Society of Anesthesiology (ASA) physical status (PS) class of the patient, and a predetermined intraoperative hypotension (IOH) risk benchmark. Treating the patient to maintain a MAP at or above the target MAP during the surgery reduces a risk of IOH during the surgery, a risk of administering an unnecessary therapy to avoid IOH during the surgery; and a risk of not administering a therapeutic MAP-decreasing action during the surgery. In some implementations, the method further comprises conducting the surgery on the patient and treating the patient to maintain the MAP of the patient at or above the target MAP during the surgery. Also provided are systems for implementing the disclosed methods.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/021 - Measuring pressure in heart or blood vessels

Abstract

Disclosed are recombinant herpes simplex virus (HSV) vectors comprising an insulator sequence comprising at least 95% identity to at least one of SEQ ID NOs: 1-4, wherein the insulator sequence comprising at least 95% identity to at least one of SEQ ID NOs: 1-4 is positioned in an intergenic region, a LAT locus, or an ICP4 locus of the vector. Also described are pharmaceutical compositions comprising the vectors and methods of using the vectors.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 35/763 - Herpes virus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Monoclonal antibodies and antigen binding fragments that specifically bind MCT11 are provided. Also disclosed are nucleic acid molecules encoding the antibody, vectors including these nucleic acid molecules, and host cells transfected with these vectors. Methods of using MCT11 specific antibodies to treat cancer, inhibit or treat T cell exhaustion, and/or enhance immunotherapy, are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Described here are ophthalmic compositions and methods for treatment of dry eye disease. One ophthalmic composition includes an effective amount of interleukin-4 (IL-4) in a free uncomplexed form, or as a complex with a dermatan sulfate. A second ophthalmic composition includes an effective amount of interleukin-13 (IL-13) in a free uncomplexed form, or as a complex with a dermatan sulfate. A third ophthalmic composition includes effective amounts of IL-4 and IL-13 in a free uncomplexed form, or as a complex with a dermatan sulfate. A fourth ophthalmic composition includes at least one activator of interleukin-4 receptor signaling in a free uncomplexed form, or as a complex with a dermatan sulfate.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 27/02 - Ophthalmic agents

Abstract

The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 agonist, a tumor necrosis factor alpha (TNFα) inhibitor, or both. The present disclosure also relates to methods of using biomarkers for identifying a subject that is likely to respond to a treatment for TBI-associated impairments, and monitoring the subject's response to such treatment.

IPC Classes  ?

• A61K 38/20 - Interleukins
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A therapeutic system or combination includes a first therapeutic agent to treat a disease condition and a second therapeutic agent adnrinistrable within a predetermined time of administration of the first therapeutic agent the second therapeutic agent inhibiting the function of Xkr8.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in any one or more of Tables 1A-1L (or a variant thereof) or according to Formula A based on such a set forth sequence, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and/or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and/or AAV capsid polypeptides are provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 5/079 - Neural cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

This document provides methods and materials involved in assessing and/or treating a mammal (e.g., a human) having cancer. For example, methods and materials that can be used to identify a cancer as being likely to respond to immune checkpoint blockade (ICB) (e.g., administration of one or more immune checkpoint inhibitors) are provided. For example, methods and materials that can be used to treat a mammal (e.g., a human) having cancer where the cancer treatment is selected based on whether or not the cancer is likely to be responsive to ICB (e.g., administration of one or more immune checkpoint inhibitors) are provided.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are methods of treating a cardiomyopathy and/or myocardial microvascular dysfunction, increasing myocardial capillary growth, reducing left ventricular hypertrophy, and/or reducing left ventricular dysfunction in a subject comprising administering an MDM2 inhibitor to the subject.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Goods & Services

Tee shirts

Abstract

Provided herein is a composition including a microparticle comprising a therapeutic agent embedded therein, wherein the microparticle comprises a silk fibroin polymer matrix and a magnetic nanoparticle.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

Compositions including metformin and their use for inhibiting or treating soft tissue musculoskeletal injuries, such as tendinopathy, and/or treating or inhibiting scar tissue are disclosed.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)

Abstract

This disclosure is directed to devices for the separation of mixtures of fluid phases. In some aspects of the disclosure, the separation device comprises an angled capillary cell. In other aspects, the separation device comprises a plurality of angled capillary cells operating in parallel. In some aspects of the disclosure, the separation device may be monolithically formed by an additive manufacturing process, such as three-dimensional printing. In some aspects of the disclosure, the separation device may function independently of gravitational direction, and without the use of filters.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Glucagon promoters are disclosed herein. In addition, disclosed are recombinant nucleic acid molecules that include a glucagon promoter operably linked to a nucleic acid molecule encoding at least one heterologous protein. Vectors including these recombinant nucleic acid molecules, and host cells transformed with these vectors, are also disclosed. Methods of use for these promoters, recombinant nucleic acid molecules, vectors and host cells are disclosed.

IPC Classes  ?

• C07K 14/605 - Glucagons
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/86 - Viral vectors

Abstract

This application relates to compounds of Formula (I) that activates the integrated stress response, compositions comprising these compounds and methods of use thereof, for example, for treating diseases, disorders or conditions treatable by activating the integrated stress response. This application relates to compounds of Formula (I) that activates the integrated stress response, compositions comprising these compounds and methods of use thereof, for example, for treating diseases, disorders or conditions treatable by activating the integrated stress response.

IPC Classes  ?

• C07D 221/12 - Phenanthridines
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

A sensor device for diagnosis of tuberculosis includes a sensor including a substrate, a first electrode, a second electrode spaced from the first electrode, and a sensor medium on the substrate between the first electrode and the second electrode. The sensor medium includes nanostructures and at least one of one or more recognition entities including at least one active binding site for Ag85 antigen. A liquid is deposited over the sensor medium. An ionic strength of the liquid is selected at which binding of the Ag85 antigen to the one or more recognition entities occurs. The ionic strength and mass loading of the one or more recognition entities immobilized on the plurality of nanostructures are selected so that an average height of immobilized recognition entities is within a determined range of a maximum mass loading at which the average height remains within a Debye screening length of the liquid.

IPC Classes  ?

• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 27/327 - Biochemical electrodes
• G01N 27/416 - Systems
• G01N 27/48 - Systems using polarography, i.e. measuring changes in current under a slowly-varying voltage
• G01N 33/483 - Physical analysis of biological material
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

bccbcc) crystal structures as anodes and current collectors, wherein the lithium-ion or lithium metal battery is dendrite free throughout the charge and discharge processes of the battery. The MCA systems include the following alloy compositions: (i) 40 atom % iron, 40 atom % aluminum or gallium, and 20 atom % magnesium, or (ii) 10 atom % iron, 40 atom % aluminum or gallium, and 50 atom % magnesium, or (iii) 50 atom % iron, 40 atom % aluminum or gallium, and 10 atom % magnesium.

IPC Classes  ?

• H01M 4/66 - Selection of materials
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 6/14 - Cells with non-aqueous electrolyte
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

Provided herein are methods of fractionating extracellular matrix (ECM) materials, producing soluble and structural fractions having different immunological activities. Also provided are compositions and devices comprising the fractions. A method of immune modulation also is provided in which an amount of a soluble or structural ECM fraction prepared according to the methods provided herein is administered to a patient in an amount effective to modulate immune function, for example macrophage function.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61L 27/52 - Hydrogels or hydrocolloids

Abstract

Methods and apparatuses for monitoring and regulating physiological states and functions are disclosed. Several embodiments include application of one or more microelectrode arrays to a dorsal root ganglion for measurement of sensory neuron activity, or stimulation of sensory reflex circuits. The methods and apparatuses can be used, for example, for monitoring or controlling bladder function in a patient.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/20 - Measuring urological functions
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• A61N 1/02 - ElectrotherapyCircuits therefor Details
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

A computational systems pathology spatial analysis platform includes: (i) a spatial heterogeneity quantification component configured for generating a global quantification of spatial heterogeneity among cells of varying phenotypes in multi-parameter cellular and subcellular imaging data; (ii) a microdomain identification component configured for identifying a plurality of microdomains for tissue samples based on the global quantification, each microdomain being associated with a a tissue sample; and (iii) a weighted graph component configured for constructing a weighted graph for the multi-parameter cellular and subcellular imaging data, the weighted graph having a plurality of nodes and a plurality of edges each being located between a pair of the nodes, wherein in the weighted graph each node is a particular one of the microdomains and the edge between each pair of microdomains in the weighted graph is indicative of a degree of similarity between the pair of the microdomains.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06T 7/00 - Image analysis
• G06V 10/426 - Graphical representations
• G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces

Abstract

Pyrvinium compounds, or a pharmaceutically acceptable salt thereof, used in methods for reducing tauopathy in a subject in need thereof. Pyrvinium compounds, or a pharmaceutically acceptable salt thereof, used in methods for treating a disease associated with accumulation of misfolded proteins (e.g., proteinopathies, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, retinitis pigmentosa such as retinitis pigmentosa with rhodopsin mutations, aging, neurodegenerative diseases, or metabolic disorders).

IPC Classes  ?

• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A piezoelectric material-based touchpad, comprising: a base structure; a plurality of support members secured in the base structure; a plurality of sensors; wherein each of the plurality of sensors is disposed on a different one of the plurality of support members, wherein each of the plurality of sensors comprises a piezoelectric material; an upper panel supported by the plurality of sensors; and a plurality of electrical insulation members; wherein each of the plurality of electrical insulation members is disposed on a different one of the plurality of sensors to insulate said sensor from the upper panel.

IPC Classes  ?

• G06F 3/0354 - Pointing devices displaced or positioned by the userAccessories therefor with detection of 2D relative movements between the device, or an operating part thereof, and a plane or surface, e.g. 2D mice, trackballs, pens or pucks
• H10N 30/30 - Piezoelectric or electrostrictive devices with mechanical input and electrical output, e.g. functioning as generators or sensors
• H10N 30/85 - Piezoelectric or electrostrictive active materials
• G06F 3/044 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means by capacitive means

Abstract

A polymer includes a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one group including a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/107 - Emulsions
• A61K 31/12 - Ketones
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 38/13 - Cyclosporins
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

Methods are disclosed for inhibiting a liver disease in a subject. These methods include administering to the subject an effective amount of a phosphodiesterase (PDE) III inhibitor or 10,12-tricosadiynoic acid (TDYA), or a pharmaceutically acceptable salt thereof, thereby treating or preventing the liver disease in the subject. Also disclosed are compositions including an effective amount of a phosphodiesterase (PDE) III inhibitor or 10,12-tricosadiynoic acid (TDYA), or a pharmaceutically acceptable salt thereof, for use in inhibiting liver disease in a subject.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods of making nanocomposite materials and nanocomposite passive components includes obtaining a base ferrite material, and reducing a material including the base ferrite material to selectively precipitate out ferromagnetic metal ions to produce a reduced material, wherein the reduced material includes a ferrite matrix having a plurality of ferrite grains and a plurality of metal nanoparticles on a surface of and/or embedded within each of the ferrite grains. Also, methods of making nanocomposite materials and nanocomposite passive components includes obtaining a. base ferrite material, creating a mixture including the base ferrite material and a plurality of metal nanoparticles, and thermally processing the mixture or a component formed using the mixture to produce the nanocomposite material/component, wherein the nanocomposite material/component includes a ferrite matrix having a plurality of ferrite grains and the plurality of metal nanoparticles on a surface of and/or embedded within each of the ferrite grains.

IPC Classes  ?

• H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
• H01F 1/36 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites in the form of particles
• H01F 27/255 - Magnetic cores made from particles
• B22F 1/054 - Nanosized particles
• C01G 45/02 - Oxides
• C01G 53/04 - Oxides
• C01G 9/02 - OxidesHydroxides

Abstract

Systems and methods using single conductor guided surface electromagnetic (EM) waves to interrogate distant wireless active or passive sensor devices or media surrounding the conductor. The guided waves may be launched on the conductor over a wide frequency range (e.g., MHz to several GHz) using an RF launcher that is connected to an interrogator. Such guided surface EM waves can travel significantly longer distances as compared to the free space propagation of waves because they travel by waveguiding along the conductor surface. Using these waves, power and/or data can be delivered to sensors located on or near the conductor surface, and data can be received from the sensors.

IPC Classes  ?

• G01N 22/02 - Investigating the presence of flaws

Abstract

This document relates to materials and methods for treating a tauopathy. For example, this document provides methods of treatment of a tauopathy that include administering a pharmaceutical preparation comprising a pharmaceutically effective amount of a compound selected from the group of staurosporine, midostaurin, and biologically active analogs thereof.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Abstract

The invention includes bioabsorbable metallic alloy coils coated with one or more of a biodegradable elastomer, polymer, polyurethane, and/or polyurethane urea, and methods for treating intracranial aneurysms and renal artery aneurysms. According to the invention, a coated, biodegradable vaso-occlusive device includes at least one endovascular coil composed of a magnesium alloy and a coating including at least one of a biodegradable elastomer, polymer, polyurethane, and polyurethane urea, applied to or deposited onto a surface of the magnesium alloy. The vaso-occlusive device is introduced into a patient's body, transported to a targeted site, and implanted at the targeted site to treat the patient having an abnormal blood flow at the targeted site.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 17/00 - Surgical instruments, devices or methods
• A61L 31/02 - Inorganic materials
• A61L 31/10 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

Selective modulators of Kv7 potassium channels that are useful for the treatment of a range of channelopathies, including epilepsy, developmental and epileptic encephalopathy, pain, tinnitus, cancer, cardiovascular disease, and neurodegeneration.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/16 - Otologicals
• A61P 35/00 - Antineoplastic agents
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07D 215/42 - Nitrogen atoms attached in position 4

Abstract

Disclosed are monoclonal antibodies, and antigen binding portions thereof, which neutralize human Lipocalin 2 (LCN-2). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also disclosed. Related methods of reducing or preventing ferroptotic death of retinal pigmented epithelium (RPE) cells, methods of reducing or preventing one or both of lipid peroxidation and inflammasome activation in RPE cells, methods of reducing or preventing a decrease in one or both of scotopic a- and b-wave responses in a retina, methods of increasing one or both of scotopic a- and b-wave responses in a retina, methods of increasing one or both of autophagy and glutathione peroxidase activity in RPE cells, and methods of treating or preventing age-related macular degeneration (AMD) are also disclosed.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 27/02 - Ophthalmic agents

Abstract

Methods, systems, and apparatus, including computer programs encoded on computer storage media, for modeling and risk assessments of abdominal aortic aneurysms. A computing system generates from a set of medical images a three-dimensional (3D) model of the aneurysm, the 3D model defining an outer wall of the aneurysm, an intraluminal thrombus (ILT) region of the aneurysm, and a luminal region of the aneurysm. The system can analyze the 3D model to determine respective values for at least one morphological feature of the aneurysm and at least one biomechanical feature of the aneurysm. Using the respective values for the at least one morphological feature of the aneurysm and the at least one biomechanical feature of the aneurysm, the system can generate a prediction of one or more outcomes related to the aneurysm.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Various perovskite solar cell embodiments include a flexible metal substrate (e.g., including a metal doped TiO2 layer), a perovskite layer, and a transparent electrode layer (e.g., including a dielectric/metal/dielectric structure), wherein the perovskite layer is provided between the flexible metal substrate and the transparent electrode layer. Also, various tandem solar cell embodiments including a perovskite solar cell and either a quantum dot solar cell, and organic solar cell or a thin film solar cell.

IPC Classes  ?

• H01G 9/20 - Light-sensitive devices
• H01G 9/00 - Electrolytic capacitors, rectifiers, detectors, switching devices, light-sensitive or temperature-sensitive devicesProcesses of their manufacture
• H01L 31/0725 - Multiple junction or tandem solar cells
• H10K 30/35 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains comprising inorganic nanostructures, e.g. CdSe nanoparticles
• H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes

Abstract

A cranial spring for treatment of craniosynostosis includes two arms that extend from a center point or center portion and have a space or gap disposed between end portions of the arms. Each of the arms can include a foot portion configured to distribute a spring force over a wider surface area of bone relative to conventional cranial springs. In some examples, the arms are linear and extend away from a curved central vertex portion, thereby giving the spring an overall U-shape or V-shape configuration. In other examples, the arms are continuously curved thereby giving the spring an overall circular shape. The spring can be formed from a bioresorbable material that is configured to dissolve after implantation over a specified resorption period, and therefore can be used in cranioplasty without requiring a second surgical procedure for removal thereof.

IPC Classes  ?

• A61F 2/28 - Bones
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
• A61B 17/68 - Internal fixation devices

Abstract

Methods are disclosed for treating a subject with an autoimmune disease. These methods include selecting a subject with the autoimmune disease that has i) an increase in ABC, DN1 cells, DN2 cells, DN3 cells and/or plasmablasts in a blood sample obtained from the subject as compared to control subjects, and/or ii) an increase of T-bet, CXCR3, CD326, VISTA, Ly6H, CD317 and/or IFNγ expressing lymphocytes as compared to a control; iii) elevated serum concentration of IL-12 and/or IFNγ as compared to a control, and/or iv) elevated anti-RNA or anti-SM antibodies as compared to a control, and administering to the subject an effective amount of IL-12 antagonist. Methods are disclosed for selecting a subject with an autoimmune disease that can be treated with an IL-12 antagonist. In some aspects, the autoimmune disease is systemic lupus erythematosus (SLE) or Sjogren's syndrome. Compositions including a therapeutically effective of an IL-12 antagonist for use in these methods are also disclosed.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 37/02 - Immunomodulators
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The disclosed concept includes systems and methods for the delivery of magnesium to a patient to modulate the human immune system and create an anti-inflammatory periodontal environment to support tissue regeneration. Various mechanisms for the delivery of magnesium include magnesium-polymer (PLGA) microparticles, magnesium-polymer (PLGA) electrospun fibers, and/or magnesium-polymer (PLGA) implant devices, e.g., scaffolds, constructed of the magnesium-polymer (PLGA) electrospun fibers. These mechanisms provide a controlled- and/or sustained-release of magnesium for the treatment of one or more of periodontitis, peri-implantitis, and bone defects. The magnesium-polymer (PLGA) microparticles include magnesium metal nanopowder that is coated with a fatty acid or lipid.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

Device, method, and system for cuffless blood pressure (BP) measurement are provided. The device, method, and system include the use of a device with a photoplethysmography (PPG)-force sensor unit, an automatic cuff device, or an oscillometric device. The disclosed subject matter is provided to improve the accuracy of the cuffless blood pressure monitoring, the accuracy of automatic arm cuff/cuffless devices, and increase signal quality of measuring devices. The disclosed subject matter can be used in conjunction with smartphones, wearables, or wrist cuffs.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/0225 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers the pressure being controlled by electric signals, e.g. derived from Korotkoff sounds
• A61B 5/026 - Measuring blood flow
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

Disclosed are lipid nano-particle pharmaceutical formulations comprising retinoic acid, and methods of using and making the formulations.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Abstract

A method of determining an extent of visual spatial neglect of a patient includes providing a software-based test to the patient via a presentation apparatus positioned on the head of the patient and having a display device positioned close and in front of the eyes of the patient. EEG information is collected from the patient during the test via an EEG apparatus positioned on the head of the patient. Portions of the EEG information collected during the test are used to determine the extent of the visual spatial neglect of the patient. An indication of the extent of the visual spatial neglect of the patient is provided.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/378 - Visual stimuli

Abstract

An article of footwear includes a sole having a bottom surface configured to contact ground when the article is worn by a wearer, a top surface opposite the bottom surface, and an inwardly directed rim extending about at least a portion of a periphery of the sole. The rim defines a channel sized to receive a peripheral edge of an insole for retaining the insole over the top surface of the sole. The article also includes an upper attached to the sole defining an opening sized to receive a foot of a wearer, the upper being configured to secure the sole to the wearers' foot.

IPC Classes  ?

• A43B 13/38 - Built-in insoles joined to uppers during the manufacturing process, e.g. structural insolesInsoles glued to shoes during the manufacturing process
• A43B 17/03 - Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined wedge-like or resilient filled with a gas, e.g. air
• A43B 17/10 - Insoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined specially adapted for sweaty feetInsoles for insertion, e.g. footbeds or inlays, for attachment to the shoe after the upper has been joined waterproof
• A43B 17/18 - Arrangements for attaching removable insoles to footwear

Abstract

A method of manufacturing a passive component for electromagnetic applications, such as power electronics applications, electromagnetic shield applications, or other high frequency microwave applications, includes creating a component body from a soft magnetic material feedstock using an additive manufacturing technique and infiltrating the component body with an infiltrant to increase a bulk density of the component. Another method of manufacturing a passive component for electromagnetic applications, such as power electronics applications, electromagnetic shield applications, or other high frequency microwave applications, includes binder jet printing a component body from a soft magnetic material feedstock and sintering the component body. The material feedstock may have an engineered particle size distribution and/or may comprise various composite materials as described herein. In addition, the sintering may include liquid-assisted sintering.

IPC Classes  ?

• B22F 1/10 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material
• B22F 1/052 - Metallic powder characterised by the size or surface area of the particles characterised by a mixture of particles of different sizes or by the particle size distribution

Abstract

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 38/19 - CytokinesLymphokinesInterferons
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 9/58 - Proteinases derived from fungi
• C12N 9/60 - Proteinases derived from fungi from yeast

Abstract

A system includes a cassette including a. first end member spaced from a second end member and a sample substrate, which is stretchable, connected between the first end member and the second end member so that a. portion of the sample substrate extends across a gap between the first end member and the second end member. The sample substrate is adapted to have a sample deposited on the portion thereof which extends across the gap. The first end member includes a first cooperating abutment member. The system also includes an assembly including a body having a sample chamber to removably receive the cassette therein and a cassette interface. The cassette interface includes an abutment member extending to contact the first cooperating abutment member. The system further includes a first actuator in connection with the body to impart motion to the first cooperating abutment member.

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation
• G02B 21/32 - Micromanipulators structurally combined with microscopes
• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
• G02B 21/34 - Microscope slides, e.g. mounting specimens on microscope slides

Abstract

The present disclosure provides a whole blood, protein-based diagnostic test for presence of unruptured aneurysms and allow for tracking progression of unruptured, ruptured, and previously treated aneurysms to guide clinical decision making. Further, the present disclosure relates to methods of treating aneurysms.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided herein is a herpes simplex virus 1 (HSV-1) recombinant virus, comprising one or more therapeutic payload sequences, wherein the genome comprises at least one alteration in each of a gene encoding infected cell polypeptides (ICP)0, a gene encoding ICP4, a gene encoding ICP22, a gene encoding ICP27 and a gene encoding ICP47, wherein the genome does not encode a functional ICP0, ICP4, ICP22, ICP27 and ICP47 protein, and wherein the genome comprises internal inverted repeat (joint) regions. Methods for using the same are also provided.

IPC Classes  ?

• A61K 35/763 - Herpes virus
• C12N 15/86 - Viral vectors
• C12N 15/869 - Herpesviral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Embodiments described herein provide for a hardware-and-software solution that effectively repurposes a patient's earphone into microphone or stethoscope, allowing a specialist to remotely perform auscultation during a remote visit. The heartbeat signal is captured and augmented from a voltage signal produced by an audio-output earphone containing phonocardiogram (PCG) signals. Hardware and software components accentuate and correct the PCG signal of the electrical signal. A patient's client device sends a clear and corrected version of the PCG signal to a provider's client device to perform cardiac auscultation.

IPC Classes  ?

• A61B 7/04 - Electric stethoscopes
• G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
• H04R 1/46 - Special adaptations for use as contact microphones, e.g. on musical instrument, on stethoscope
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Provided herein is a computer-implemented method of controlling autonomic balance in a patient, including receiving, with at least one processor and from at least one sensor, data relating to autonomic tone in the patient, determining, with at least one processor and based at least in part on a machine learning model applied to the data relating to autonomic tone, whether sympathetic tone in the patient should be decreased and/or parasympathetic tone in the patient should be increased, and delivering, through an implantable device and based at least in part on the determination, stimulation to the patient's sympathetic nervous system and/or parasympathetic nervous system, thereby controlling autonomic balance in the patient.

Abstract

Disclosed herein are embodiments of a polymer-based gel implant and methods of making and using the same. The polymer-based gel implant comprises a polymer component and a therapeutic agent. In some embodiments, the polymer-based gel implant can be used to treat and/or prevent retinal diseases and/or retinopathies. The polymer-based gel implant exhibits physical properties that provide the ability to safely place the polymer-based gel implant in an ocular region without undesired diffusion and also to allow for controlled and timely release of the therapeutic agent to a desired region of the ocular region, such as the retina. In particular disclosed embodiments, the polymer-based gel implant can be used for safe and effective gene therapy.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention relates to compounds of Formula (I): The present invention relates to compounds of Formula (I): where R1, R2, X, s, and p are as defined herein. The present invention also relates to compounds of Formula (II), Formula (III), and: The present invention relates to compounds of Formula (I): where R1, R2, X, s, and p are as defined herein. The present invention also relates to compounds of Formula (II), Formula (III), and: where R1a, R1b, R1d, R2a, R2b, R3b, X, Z, Z1, Z2, s, and p are as defined herein. Methods of using these compounds to regulate Cav2.2.target double-stranded RNA and to treat diseases and disorders, e.g., chronic pain, are also disclosed.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/18 - Sulfonamides
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
• C07C 311/19 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction

Abstract

Devices, systems, and methods to produce Ac-225 from Ra-226 using gamma-radiation generator are disclosed herein. The gamma radiation generator can utilize an electronic neutron generator or a nuclear reactor to produce high energy prompt-capture gamma-radiation. The Ra-226 is irradiated by the gamma radiation to produce Ra-225, which decays to produce Ac-225. The method of using electronic neutron generator and an irradiation target material such as Gd-157 to produce high energy gamma radiation without using a continuously decaying radioisotope such as Co-60 could significantly reduce the cost and increase the safety associated with the production of high energy gamma radiation and Ac-225.

IPC Classes  ?

• G21G 1/12 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by electromagnetic irradiation, e.g. with gamma or X-rays
• G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes

Abstract

A system may include a plurality of compartments, wherein each compartment defines a respective internal volume. A system may include a plurality of odorous materials, wherein each compartment houses a respective odorous material within the respective internal volume. A system may include an integrated circuit (IC) chip comprising a processor and a memory, the memory having computer-executable instructions stored thereon that, when executed by the processor, cause the IC chip to monitor a respective state of each compartment.

IPC Classes  ?

• A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis

Abstract

The invention provides an integrated multi-channel battery analyzer including one or more measurement units and accompanying pluggable battery capsules that physically and electrically connect to the measurement unit(s) to obtain multiple measurements simultaneously of electro-chemical properties for flowable materials, e.g., flowable batteries. The battery capsules are in a stacked configuration and include electrical components, e.g., positive and negative electrodes, and positive and negative flow channels through which the positive and negative electrolyte travels, respectively, as well as a separator positioned between the flow channels, and at least one pump. In addition, the battery capsules have a small size as compared to battery capsules known in the art.

IPC Classes  ?

• G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
• G01N 27/416 - Systems
• H01M 8/04537 - Electric variables
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present disclosure relates to compositions and methods for preventing and/or treating corneal scarring. The present disclosure further provides kits for performing such methods.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

Recombinant TGF-β2 monomers engineered to prevent dimerization and block TGF-β signaling are described. The engineered monomers lack the ability to bind and recruit TGF-β type I receptor (TbRI), but retain the capacity to bind the high affinity TGF-β type II receptor (TbRII). The TGF-β2 monomers also include additional modifications that increase their affinity for TbRII, reduce their aggregation and/or improve their folding. Nucleic acid molecules and vectors encoding the recombinant TGF-β2 monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-β2 monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-β2 monomers and/or cells producing the recombinant TGF-β2 monomers, to inhibit TGF-β signaling, such as to treat disorders associated with aberrant TGF-β signaling, are also described.

IPC Classes  ?

• C07K 14/495 - Transforming growth factor [TGF]
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

A method including administering a therapeutically effective amount of a therapeutic agent to a subject for improving exercise performance, treating obesity, fatty liver, rhabdomyolysis, Leigh syndrome, mitochondrial Complex I deficiency, fatty acid oxidation disorders, lactic acidosis, metformin toxicity, ischemic acute kidney injury, or nephrotoxin-induced kidney injury, wherein the therapeutic agent is a straight-chain saturated dicarboxylic acid of 8 to 12 carbons in length, a triglyceride made from a straight-chain saturated dicarboxylic acid of 8 to 12 carbons in length, a metabolic intermediate produced during the catabolic chain-shortening of a straight-chain dicarboxylic acid of 8 to 12 carbons in length, a salt thereof, or a mixture thereof.

IPC Classes  ?

• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A compound of formula I, or a stereoisomer, isotopomer, tautomer, or pharmaceutically acceptable salt thereof: wherein a ligand that binds to a Nef protein (NB) is covalently attached via a linker (L) to a ligand that binds to a E3 ligase cereblon (CB).

IPC Classes  ?

• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil

Abstract

Methods for preventing and/or treating a cardiometabolic disease, e.g., heart failure with preserved ejection fraction (HFpEF) using Adropin are provided herein. The presently disclosed subject matter further relates to gene therapy methods for providing endogenous production of Adropin.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

A formulation includes nanostructures formed from self-assembly of a plurality of amphiphilic polymers comprising cationic groups. Each of the nanostructures includes an application thereon or added thereto. The application inc hides a negatively charged targeting agent.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/107 - Emulsions
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided herein is a method of inducing colon contractions/defecation or penile erection in a patient, including stimulating one or more sacral roots of the patient's spinal cord with a plurality of electrical pulses, wherein the electrical pulses are delivered at a frequency of from about 3 Hz to about 10 Hz or from about 10 Hz to about 80 Hz.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a CD276 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a CD276 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a CD94/NKG2A polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a CD94/NKG2A polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer and/or a viral infection are provided.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

Provided herein are single-domain antigen binding molecules able to bind uPAR. Also provided herein are methods of treating cancer, fibrotic disease, or diseases related to senescent cell phenotypes in which uPAR is expressed.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to ex-situ biosensors that impedimetrically detect one or more target biomarkers of interest in a bodily fluid sample derived from a patient. The biosensors include a multi-array of conducting material, such as platinum wires, having immobilized thereon antibody and/or aptamer that is selected to specifically and selectively bind to the one or more target biomarkers of interest. The biosensors are contacted with a portion of the bodily fluid sample, and the antibody and/or aptamer binds to the target biomarker(s) of interest in the bodily fluid sample. As a result, an electrochemical impedance signal is generated and therefore, a change in the electrochemical impedance is indicative of the presence of the target biomarker(s) of interest in the bodily fluid sample. The biosensors are point-of-care, on-demand devices that can be used in a medical environment, as well as in domestic and health emergency settings.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Embodiments are provided for stimulation of somatosensory cortex such that (i) the perceptions of force induced thereby exhibit increased levels of discrimination, allowed for finer-resolution perceptions to be achieved, (ii) perceptions of edges or other geometric aspects of objects can be delivered, and (iii) perceptions of motion of objects can be delivered. These embodiments include providing such stimulation to multiple electrodes or other stimulation sites synchronously, with the multiple stimulation sites evoking perceptions whose locations on the hand at least partially overlap. Perception of edges can be evoked by synchronously stimulating multiple stimulation sites somatotopically oriented along the orientation of the edge. Perception of motion can be evoked by providing sequential stimulus from one stimulation site to another, with the interval between sequential stimuli non-overlapping enough to induce perception of motion while close enough in time to evoke a single percept rather than a sequence of discrete percepts.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61F 2/72 - Bioelectric control, e.g. myoelectric
• A61F 2/54 - Artificial arms or hands or parts thereof

Abstract

A method of determining the presence and/or severity of a pulmonary disease in an individual first includes directing an ultrasound signal generated by a speaker of an device into an airway of the individual through an interface coupled to the device. The interface includes a mouthpiece to be received in a mouth of the individual. The method further includes receiving with a microphone of the device a reflected version of the ultrasound signal from the airway and determining from the reflected version of the ultrasound signal the presence and/or severity of the pulmonary disease in the individual. The presence and/or severity of the pulmonary disease is determined using a trained machine learning model of a controller of the device

IPC Classes  ?

• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 7/00 - Instruments for auscultation
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 8/08 - Clinical applications
• A61M 16/04 - Tracheal tubes

Abstract

A simulation device for an epidural block procedure includes an elongated internal frame formed from an ultrasound opaque material defining an axially extending channel accessible through a widened funnel portion of the internal frame. The simulation device also includes a barrier positioned in the channel representative of anatomical structures that should not be contacted by an epidural needle and a body formed from an ultrasound penetrable material molded about and at least partially enclosing the internal frame configured to be pierced by the epidural needle. The internal frame is positioned so that the epidural needle can be inserted through a surface of the body and into the channel through the funnel portion to simulate insertion of the epidural needle into an epidural space during the epidural block procedure.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 23/30 - Anatomical models

Abstract

Use of PRDX6 is a predictive survival marker for several tumor types and drug targets, as well as using PRDX6 inhibitors to sensitize cancer cells to HDACi, PD1 and PD-L1 inhibitors.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/18 - Sulfonamides
• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• A61K 38/15 - DepsipeptidesDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof cyclic, e.g. valinomycins
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Goods & Services

Providing medical research, health research and scientific research information in the field of clinical trials, compiling data for research purposes in the field of clinical trials, and scientific research in the field of clinical trials, and medical and health research services to provide evidence to help patients, caregivers, clinicians and others to make informed decisions Providing medical information to patients, caregivers, clinicians and others to help them make informed decisions; analysis of medical database

Abstract

Provided are compounds of Formula I or Formula II, or their pharmaceutically acceptable salts, solvates, hydrates, tautomers, or stereoisomers for enhancing the cellular uptake of antisense oligonucleotides. The compounds install the artificial nucleotide 5-dihydroxyboryluridine in a site-specific manner within drug-like antisense oligonucleotides. The provided compounds have enhanced cytosolic penetration and splice-correcting activity compared to non-boron-containing analogs.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/69 - Boron compounds
• A61K 31/66 - Phosphorus compounds
• A61K 31/33 - Heterocyclic compounds

Abstract

Disclosed herein are methods for treating impairment of a limb in a subject. Particular methods comprise applying a therapeutically effective amount of an electrical stimulus to dorsal roots, dorsal rootlets, or dorsal root ganglia, of sensory neurons innervating the limb of the subject, wherein the impairment is a motor impairment and/or a proprioception impairment due to neurological disorder or injury, the electrical stimulus is applied with one or more electrodes controlled by a neurostimulator, and the one or more electrodes are implanted in the epidural space at the dorsolateral aspect of the spinal cord and proximate to the dorsal roots or dorsal rootlets of the sensory neurons innervating the limb of the subject, or the one or more electrodes are implanted proximate to dorsal root ganglia of sensory neurons innervating the limb of the subject.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

The object of the present invention is an implantable medical device comprising a biodegradable shape-memory polymeric material, wherein said polymeric material is a polyurethane copolymer. Furthermore, the invention relates to the implantable medical device comprising at least one drug or a molecule with pharmacological activity.

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/34 - Macromolecular materials

Abstract

Provided herein are methods of producing regulatory dendritic cells from donor organ perfusate, and use of the donor regulatory dendritic cells for transplantation.

IPC Classes  ?

• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to a polymeric antireflective coating film for a photoelectric device and a method of manufacturing the same. More specifically, the polymeric antireflective coating film includes a transparent polymer, and micro phosphor particles and oxide nanoparticles, wherein a textured surface of a three-dimensional (3D) structure is included on at least one surface thereof.

IPC Classes  ?

• C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes
• C08K 3/34 - Silicon-containing compounds
• C08K 3/36 - Silica
• C09D 7/61 - Additives non-macromolecular inorganic
• C09D 183/04 - Polysiloxanes
• C09K 11/59 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing silicon
• H01L 31/0216 - Coatings

Abstract

Described herein are prediction models based on the transcriptomic, exomic, and/or radiological analyses on tissue samples to predict the likelihood of the original cancer (such as Hepatocellular carcinoma (HCC)) recurrence into the liver transplant. An example computer implemented method for predicting the likelihood of liver cancer recurrence 5 into a liver transplant includes receiving gene expression data related to a liver tissue sample for a subject having a liver cancer, inputting the gene expression data into a trained machine learning model, and predicting, using the trained machine learning model, a risk of recurrence of the liver cancer in the subject after liver transplantation.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a PSMA polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a PSMA polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

Methods are provided for treating acute graft rejection in allograft recipients. Druggable genes are identified, and therapeutic agents directed to lowering expression of those genes, including reducing activity of their gene products, are provided. Treatment may be personalized by including a step of identification of overexpressed genes in a patient, and tailoring treatment to the transcriptome of the patient's PBMC's or allograft by sequencing methods (bulk or single-cell) or spatial transcriptomics of a biopsy of the allograft.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A compound, or a stereoisomer, isotopomer, tautomer, or salt thereof having a structure of: A-L-B wherein A is a ligand that can covalently bioconjugate to an unnatural amino acid bearing a tetrazine or other reactive handle, incorporated into a protein; L is a linker covalently attaching A and B; and B is a ligand that can bind to a E3 ligase.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Abstract

A probe can be situated within a tissue to perfuse one or more materials, collect material in response, and pass the collected material to a microdialysis probe situated external to the tissue based on fluid flow by electroosmosis. Perfusion and collection can be via orifices that are offset laterally and along a tissue depth. Variation of perfusion by varying materials perfused or rate of perfusion can be used to determine perfusion rates or other time-dependencies., concentrations of chemical species and rates of reactions of chemical species in the tissue.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value

Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) to an NE polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, and/or antibody domains) that bind to an NE polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer and/or an inflammatory condition are provided.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

A system for fractionating multiple fractions of particles from a sample includes a fractionation unit including a flow channel divided into two or more compartments by one or more porous membranes of known pore size and a flow module system in fluid connection with the fractionation unit. The flow module system further includes a sample container for the sample, a backwash container for a backwash fluid, and two or more collection containers for collection of fractionated portions of the sample, each of the collection containers being in fluid connection with a different one of the compartments. The system further includes a control system in operative connection with the flow module system to control flow.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

A metamaterial, comprising: an auxetic lattice structure with snap-through buckling behavior comprising a plurality of rows; wherein the lattice defines a holey arrangement array; and cement, concrete or any other brittle materials disposed in the auxetic lattice structure.

IPC Classes  ?

• E04B 5/43 - Floor structures of extraordinary designFeatures relating to the elastic stabilityFloor structures specially designed for resting on columns only, e.g. mushroom floors
• C04B 24/28 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• C04B 28/04 - Portland cements

Abstract

A cranial electronics device includes electronics and a flexible body via which the electronics are carried. The flexible body and the electronics are formed such that the device has a lower surface approximating a contour of an outer surface of a portion of a patient's skull. The cranial electronics device is configured to be implanted between the patient's scalp and the portion of patient's skull.

IPC Classes  ?

• A61N 1/375 - Constructional arrangements, e.g. casings
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• A61N 1/378 - Electrical supply

Abstract

A needle system for implanting an extending element including a needle body-configured to be placed in closed state and in open state, wherein an axially extending opening is provided in the needle body in the open state, whereby the extending element, which has been passed through a lumen of the needle body, can be removed from the lumen via the axially extending opening.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

This document relates to methods and materials involved in assessing a mammal (e.g., a human) having cancer (e.g., metastatic cancer), preparing a treatment for a mammal (e.g., a human) having cancer (e.g., metastatic cancer), and/or treating a mammal (e.g., a human) having cancer (e.g., metastatic cancer). For example, methods and materials for identifying a cancer (e.g., metastatic cancer) as being likely to respond to an adoptive cell therapy (e.g., a tumor infiltrating lymphocyte therapy) are provided.

Abstract

A system for performing a surgical procedure with a powered surgical device which is configured to be connected to a power source to power a tissue-interacting element of the powered surgical device, includes electronic circuitry configured to be placed in connection with the powered, surgical device and a sensor system in communicative connection with the electronic circuitry. The sensor system is configured to measure values of one or more variables related to a risk of injury to non-targeted tissue over time during the surgical procedure. The electronic circuitry is configured to control the tissue-interacting element as a function of the measured values of the one or more variables.

IPC Classes  ?

• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• A61B 18/14 - Probes or electrodes therefor

Abstract

Disclosed are methods for treating muscle wasting diseases, such as spinal muscular atrophy, or muscular dystrophies, using matrix bound vesicles (MBV). Compositions for use in treating a muscle wasting disease are also disclosed.

IPC Classes  ?

• A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 37/02 - Immunomodulators
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0786 - MonocytesMacrophages

Abstract

Provided are heterocyclic compounds of Formula I or Formula II or their pharmaceutically pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers for imaging tau aggregates. Compounds of Formula I or Formula II may be used for the detection of tau aggregates in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Abstract

A method of treating an inherited ocular disorder associated with or caused by a misfolded ocular protein in a subject in need thereof includes administering to the subject a compound that promotes clearance of misfolded ocular protein.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 27/02 - Ophthalmic agents

Abstract

Provided herein are stable hypotonic or isotonic formulations containing active ingredients, such as antiviral compositions, or anti-retroviral compositions for intrarectal delivery to provide prophylaxis against viral infections.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Ultrasound systems and methods of use are provided for rapidly heating a target area of a subject. The ultrasound system can include at least one imaging transducer array for imaging the target area, and at least two spaced-apart heating transducer arrays for heating the target area. The heating transducer arrays can be separated by the imaging transducer array on an ultrasound probe.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

Provided herein is a ligament ECM soluble fraction useful for the growth and regrowth of ligament tissue. Methods of preparation of the soluble fractions and use of the soluble fractions in growth or regrowth of ligament tissue also are provided.

IPC Classes  ?

• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

Abstract

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a PSCA polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a PSCA polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present disclosure provides compounds of Formula (I) and (II), or pharmaceutically acceptable salts or isotopic variants thereof, wherein, R1to R7122, R20-R25, R31-R34122, and a-e are defined herein. Also provided are methods of modulating alpha-synuclein in a patient in need thereof and methods of treating a neurodegenerative disorder in a patient in need thereof using one or more compounds described herein.

IPC Classes  ?

• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
• C07D 213/72 - Nitrogen atoms
• C07D 239/46 - Two or more oxygen, sulfur or nitrogen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/08 - Bridged systems
• C07D 471/10 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 487/08 - Bridged systems
• C07D 487/10 - Spiro-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

Described herein are systems and methods for assembling electron spin and charge to possess one or more properties of a magnetic monopole. Example systems can include a laser configured to generate a light beam with a first spin and/or a first orbital angular momentum, and a surface including a coupling structure having a geometrical charge. When exposed to the light beam, the surface is configured to enable excitations of surface plasmon polariton field waves at metal-dielectric interfaces of the coupling structure to generate a plasmonic field. The surface can be configured to focus the plasmonic field to form a plasmonic vortex, in which plasmonic spin-orbit coupling between a total spin and a total orbital angular momentum forms a topological spin texture that is homotopic to that of a magnetic monopole.

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
• G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators

Abstract

Embodiments described herein provide for a healthcare ecosystem of computing devices collecting disparate types (e.g., multimodal) of subject data and developing patient digital twins as predictive models configured to predict experimental outcomes for subjects. The system may inform clinicians of subject attributes for preparing microphysiology systems, sometimes referred to as "patient biomimetic twins" (PBTs), having attributes or disease derived from cells that can be used for experimentally testing the predictions generated by the predictive model of the PDT.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
• G06N 20/00 - Machine learning
• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data